The Lancet publishes studies showing Roche’s faricimab improved and maintained vision in two leading causes of vision loss, extending time between treatments up to four months January 24, 2022February 22, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: The Lancet publishes studies showing Roche’s…New two-year data for Roche’s Vabysmo and Susvimo…New two-year data for Roche’s Vabysmo and Susvimo…FDA approves Roche’s Vabysmo, the first bispecific…FDA approves Roche’s Vabysmo, the first bispecific…CHMP recommends EU approval of Roche’s Vabysmo, the…
